Humanigen jumps over 10% after peer-reviewed data on COVID-19 therapy

Creative Thinking/iStock via Getty Images

• Clinical-stage biotech Humanigen (NASDAQ:HGEN) rose more than 10% on Wednesday after the company announced a peer-reviewed publication of data supporting its investigational COVID-19 therapy lenzilumab.
• The publication in the medical journal Thorax was based on the data from the company’s Phase 3 LIVE-AIR study.
• The data illustrate the function of C-reactive protein (CRP) in identifying patients who will likely receive the greatest benefit of lenzilumab.
• The LIVE-AIR study involving hospitalized COVID-19 patients point to a strong relationship between CRP and outcomes with lenzilumab treatment.
• Those who received lenzilumab with a baseline CRP of less than 150 mg/L were found to have the greatest clinical benefit, the company said, noting a 62% reduction in the relative risk of invasive mechanical ventilation and death compared to those who received the placebo.
• Read: Last month, Humanigen (HGEN) partnered with PCI Pharma Services to introduce lenzilumab in the U.K. market.

Comments

[Downtown10]

Top line results expected from the NIH for the Lenzilumab ACTIV-5 trial in July. Stock is on life support (ECMO?), but it’s not dead yet. Needs to get Lenzilumab approved somewhere. I’m not optimistic about the FDA given their Big Pharma bias.